These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30879942)

  • 1. Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?
    Mouzaki M; Shah A; Arce-Clachar AC; Hardy J; Bramlage K; Xanthakos SA
    J Clin Lipidol; 2019; 13(3):425-431. PubMed ID: 30879942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology.
    Della Corte C; Fintini D; Giordano U; Cappa M; Brufani C; Majo F; Mennini C; Nobili V
    Clin Endocrinol (Oxf); 2013 Jul; 79(1):49-54. PubMed ID: 22789032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia.
    Rimbert A; Vanhoye X; Coulibaly D; Marrec M; Pichelin M; Charrière S; Peretti N; Valéro R; Wargny M; Carrié A; Lindenbaum P; Deleuze JF; Genin E; Redon R; Rollat-Farnier PA; Goxe D; Degraef G; Marmontel O; Divry E; Bigot-Corbel E; Moulin P; Cariou B; Di Filippo M
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e63-e71. PubMed ID: 33207932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
    Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
    Vilar-Gomez E; Gawrieh S; Liang T; McIntyre AD; Hegele RA; Chalasani N
    J Clin Lipidol; 2021; 15(2):275-291. PubMed ID: 33454241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Janus-faced manifestations of homozygous familial hypobetalipoproteinemia due to apolipoprotein B truncations.
    Di Leo E; Eminoglu T; Magnolo L; Bolkent MG; Tümer L; Okur I; Tarugi P
    J Clin Lipidol; 2015; 9(3):400-5. PubMed ID: 26073401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia is associated with pediatric nonalcoholic fatty liver disease.
    Dowla S; Aslibekyan S; Goss A; Fontaine K; Ashraf AP
    J Clin Lipidol; 2018; 12(4):981-987. PubMed ID: 29699915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 13. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease.
    Mann JP; De Vito R; Mosca A; Alisi A; Armstrong MJ; Raponi M; Baumann U; Nobili V
    Hepatology; 2016 Mar; 63(3):745-53. PubMed ID: 26638195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis.
    Lam MC; Singham J; Hegele RA; Riazy M; Hiob MA; Francis G; Steinbrecher UP
    Case Rep Gastroenterol; 2012 May; 6(2):429-37. PubMed ID: 22855658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study.
    Nass KJ; van den Berg EH; Faber KN; Schreuder TCMA; Blokzijl H; Dullaart RPF
    Metabolism; 2017 Jul; 72():37-46. PubMed ID: 28641782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease.
    Jaafar RF; Hajj Ali AM; Zaghal AM; Kanso M; Habib SG; Halaoui AF; Daniel F; Mokaddem F; Khalife MJ; Mukherji DM; Faraj WG
    Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1540-1544. PubMed ID: 31135513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.
    Sonmez A; Nikolic D; Dogru T; Ercin CN; Genc H; Cesur M; Tapan S; Karslioğlu Y; Montalto G; Banach M; Toth PP; Bagci S; Rizzo M
    J Clin Lipidol; 2015; 9(4):576-82. PubMed ID: 26228676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
    Kim GH; Chung JW; Lee JH; Ok KS; Jang ES; Kim J; Shin CM; Park YS; Hwang JH; Jeong SH; Kim N; Lee DH; Kim JW
    Clin Mol Hepatol; 2015 Dec; 21(4):379-86. PubMed ID: 26770927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Hepatic Tissue Copper in Pediatric Nonalcoholic Fatty Liver Disease.
    Mendoza M; Caltharp S; Song M; Collin L; Konomi JV; McClain CJ; Vos MB
    J Pediatr Gastroenterol Nutr; 2017 Jul; 65(1):89-92. PubMed ID: 28644356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.